Cell Cytotoxicity Assay Services

Cytotoxicity Assays are widely used by researchers and by the pharmaceutical industry to investigate the toxicity of compounds on cellular systems. Cytotoxicity assays provide a rapid, sensitive and validated approach to quantify harmful-dose ranges of compounds and to analyze the biological effects of toxicity on living cellular systems. Additionally, cytotoxicity testing can be used for quality control purposes for lot release testing of raw materials or of manufactured drug products.

Cell Cytotoxicity Assay

Medicilon can offer multiple readouts for quantifying the cytotoxicity of compounds, including colorimetric, fluorescent and luminescent assays that can be multiplexed with apoptosis or viability measurements. Our wide range of testing platforms includes the MultiTox-Glo Multiplex Cytotoxicity Assay and the ApoGlow, MTT, XTT, MTS, and LDH assays.

Available Cytotoxicity Assay:

Agarose Overlay
MEM Elution
Direct Contact Cytotoxicity
Indirect Contact Agar Diffusion Test
MTT Assay (quantitative)

In Vitro Toxicity Screening Services

In vitro testing using primary cells can quickly screen for new chemical entities with serious toxicology consequences. Using primary cells derived from human tissues, the relative risk can be determined in multiple organs over a population of donors. The following in vitro cytotoxicity assays using the specified endpoints have been developed in our laboratory. With our ready inventory of human and cynomolgus monkey, cells scheduling is not an issue. Contact IVAL to begin designing your study today.

Cell viability (luminescence based ATP assay)
Cell growth and survival (MTT/WST-1 metabolism)
Apoptosis
Oxidative Stress

Cytotoxicity is typically defined as the loss of membrane integrity as measured by membrane-impermeable dye uptake or the release of intracellular enzymes into the extracellular media. Promega offers multiple readouts for quantifying cytotoxicity.

Cytotoxicity assays

1.CytoTox-Glo Cytotoxicity Assay

The CytoTox-Glo Assay is the most sensitive method available for measuring cytotoxicity. The assay quantifies the extracellular activity of an intracellular protease (dead-cell protease) when the protease is released from membranecompromised cells. The amount of luminescence directly correlates with the percentage of cells undergoing cytotoxic stress.

2.CytoTox 96 Non-Radioactive Cytotoxicity Assay

The CytoTox 96 Assay is a colorimetric alternative to 51Cr release cytotoxicity assays. The CytoTox 96 Assay quantitatively measures lactate dehydrogenase (LDH),a stable cytosolic enzyme that is released upon cell lysis, in much the same way as 51Cr is released in radioactive assays.

3.CytoTox-ONE Homogeneous Membrane Integrity Assay
The CytoTox-ONE Assay is a fluorescent method to rapidly measure the activity of lactate dehydrogenase (LDH) released into the culture medium from cells with damaged cell membranes (non-viable cells). The amount of fluorescent product produced is proportional to the number of dead cells present.

What We Have:

Complete range of Cytoxicity markers
Single and multiple parameters from 1 cellular sample
High throughput screening methods
Easy handling, less hands-on time

Reduced amount of test compound and cells with the multiple parameter test kits

Contact Us

Email : marketing@medicilon.com

Tel : +86 021 58591500

Tips : Above is part of cell cytotoxicity assay,cytotoxicity testing, in vitro cytotoxicity assay, in vivo cytotoxicity assay . You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客